Blueprint Medicines logo

Blueprint MedicinesNASDAQ: BPMC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 April 2015

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$6.02 B
-21%vs. 3y high
90%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
96%vs. sector
-77%vs. 3y high
82%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:07:00 GMT
$94.81-$0.14(-0.15%)

Dividend

No data over the past 3 years
$128.18 M$145.32 M
$128.18 M-$56.28 M

Analysts recommendations

Institutional Ownership

BPMC Latest News

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
seekingalpha.com15 November 2024 Sentiment: POSITIVE

Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
zacks.com31 October 2024 Sentiment: POSITIVE

Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.

Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
zacks.com30 October 2024 Sentiment: POSITIVE

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
prnewswire.com30 October 2024 Sentiment: POSITIVE

-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
zacks.com24 October 2024 Sentiment: POSITIVE

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
zacks.com23 October 2024 Sentiment: NEGATIVE

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
zacks.com21 October 2024 Sentiment: POSITIVE

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
prnewswire.com16 October 2024 Sentiment: NEUTRAL

CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions
accesswire.com09 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Blueprint Medicines?

Blueprint Medicines Corporation is a precision therapy company specializing in genomic cancer diseases, rare diseases, and cancer immunotherapy. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines Corporation is developing the following drugs: avapritinib - for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263 - an oral potent inhibitor for the treatment of indolent SM and other mast cell diseases; fisogatinib - an oral potent inhibitor currently in phase I clinical trials for the treatment of hepatocellular carcinoma and other drugs for the treatment of rare genomic and tumor diseases.

What sector is Blueprint Medicines in?

Blueprint Medicines is in the Healthcare sector

What industry is Blueprint Medicines in?

Blueprint Medicines is in the Biotechnology industry

What country is Blueprint Medicines from?

Blueprint Medicines is headquartered in United States

When did Blueprint Medicines go public?

Blueprint Medicines initial public offering (IPO) was on 30 April 2015

What is Blueprint Medicines website?

https://www.blueprintmedicines.com

Is Blueprint Medicines in the S&P 500?

No, Blueprint Medicines is not included in the S&P 500 index

Is Blueprint Medicines in the NASDAQ 100?

No, Blueprint Medicines is not included in the NASDAQ 100 index

Is Blueprint Medicines in the Dow Jones?

No, Blueprint Medicines is not included in the Dow Jones index

When was Blueprint Medicines the previous earnings report?

No data

When does Blueprint Medicines earnings report?

The next expected earnings date for Blueprint Medicines is 14 February 2025